Skip to Content

Kengreal Approval History

Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.

FDA Approval History for Kengreal

DateArticle
Jun 22, 2015Approval FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention
Apr 15, 2015FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor
Apr 30, 2014The Medicines Company Receives Complete Response Letter From FDA for Antiplatelet Agent Cangrelor
Feb 12, 2014FDA Advisory Committee Recommends Against Antiplatelet Therapy Cangrelor
Sep  3, 2013Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published
Jul  1, 2013FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide